3SBio Licenses PD-1/VEGF Bispecific Antibody to Pfizer in Deal Worth 9 Trillion Won, Including 1.9 Trillion Won Upfront Payment

Aspen Neuroscience and Bambusa Plan U.S. IPOs; Developers of Parkinson’s and Bispecific Antibody Therapies

St. Jude Identifies Cell Marker for High-Risk Neuroblastoma

University of Texas at Austin Develops Flexible Electrode for Recording Brain Waves for a Month Without Shaving Hair

Revolution Medicines Shares Fall 6.3% on Concerns About RASONK’s KRAS Subgroup

GSK Adopts Chai Discovery AI Model After Wet-Lab Validation

Teva Wins FDA Approval for Long-Acting Olanzapine Beltruzza for Schizophrenia